BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 26851441)

  • 1. A focal adhesion kinase inhibitor 16-hydroxy-cleroda-3,13-dien-16,15-olide incorporated into enteric-coated nanoparticles for controlled anti-glioma drug delivery.
    Thiyagarajan V; Lin SX; Lee CH; Weng CF
    Colloids Surf B Biointerfaces; 2016 May; 141():120-131. PubMed ID: 26851441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel inhibitor, 16-hydroxy-cleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking.
    Thiyagarajan V; Lin SH; Chia YC; Weng CF
    Biochim Biophys Acta; 2013 Aug; 1830(8):4091-101. PubMed ID: 23628706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facile synthesis of pH sensitive polymer-coated mesoporous silica nanoparticles and their application in drug delivery.
    Tang H; Guo J; Sun Y; Chang B; Ren Q; Yang W
    Int J Pharm; 2011 Dec; 421(2):388-96. PubMed ID: 22001840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 16-hydroxy-cleroda-3,13-dien-16,15-olide induced glioma cell autophagy via ROS generation and activation of p38 MAPK and ERK-1/2.
    Thiyagarajan V; Sivalingam KS; Viswanadha VP; Weng CF
    Environ Toxicol Pharmacol; 2016 Jul; 45():202-11. PubMed ID: 27318969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-Sensitive drug delivery system based on modified dextrin coated mesoporous silica nanoparticles.
    Chen H; Zheng D; Liu J; Kuang Y; Li Q; Zhang M; Ye H; Qin H; Xu Y; Li C; Jiang B
    Int J Biol Macromol; 2016 Apr; 85():596-603. PubMed ID: 26776872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation.
    Guha A; Biswas N; Bhattacharjee K; Sahoo N; Kuotsu K
    Drug Deliv; 2016 Nov; 23(9):3552-3561. PubMed ID: 27540687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tailor-made pH-sensitive polyacrylic acid functionalized mesoporous silica nanoparticles for efficient and controlled delivery of anti-cancer drug Etoposide.
    Saroj S; Rajput SJ
    Drug Dev Ind Pharm; 2018 Jul; 44(7):1198-1211. PubMed ID: 29412022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Graft to" Synthesis and Ibuprofen-Loading Performance of pH-Sensitive PMAA-Silica Hybrid Nanoparticles with Controlled Bimodal Mesopores.
    Han J; Sun J; Bai S; Panezai H; Jin X; Wu X
    J Pharm Sci; 2015 Dec; 104(12):4299-4306. PubMed ID: 26501935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
    Biswas N
    Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery.
    He Y; Luo L; Liang S; Long M; Xu H
    J Biomater Appl; 2017 Oct; 32(4):524-532. PubMed ID: 28776488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesoporous silica as topical nanocarriers for quercetin: characterization and in vitro studies.
    Sapino S; Ugazio E; Gastaldi L; Miletto I; Berlier G; Zonari D; Oliaro-Bosso S
    Eur J Pharm Biopharm; 2015 Jan; 89():116-25. PubMed ID: 25478737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
    Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
    Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
    Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Evaluation of pH Responsive Doxazosin Loaded Mesoporous Silica Nanoparticles: A Smart Approach in Drug Delivery.
    Guha A; Biswas N; Bhattacharjee K; Das P; Kuotsu K
    Curr Drug Deliv; 2016; 13(4):574-81. PubMed ID: 26201344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control-release microcapsule of famotidine loaded biomimetic synthesized mesoporous silica nanoparticles: Controlled release effect and enhanced stomach adhesion in vitro.
    Li J; Wang H; Yang B; Xu L; Zheng N; Chen H; Li S
    Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():273-7. PubMed ID: 26478311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer.
    Li T; Chen X; Liu Y; Fan L; Lin L; Xu Y; Chen S; Shao J
    Eur J Pharm Sci; 2017 Jan; 96():456-463. PubMed ID: 27771513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facile Synthesis of Three Types of Mesoporous Silica Microspheres as Drug Delivery Carriers and their Sustained-Release Properties.
    Zhu Y; Wang B; Chen J; He J; Qiu X
    Curr Drug Deliv; 2023; 20(9):1337-1350. PubMed ID: 35713141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
    Yan Y; Fu J; Wang T; Lu X
    Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
    Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
    Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 43.